Switch strategies in the management of hypertension: A cost minimisation analysis of angiotensin receptor blocker based regimen

Current Medical Research and Opinion

Volumn 24, Issue 2, 2008, Pages 581-589

  Belsey, Jonathan ^a  

^a JB Medical Ltd   (United Kingdom)

Author keywords

Angiotensin receptor blockers; Cost analysis; Hypertension; Losartan; Switching

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BENDROFLUMETHIAZIDE; CANDESARTAN; IRBESARTAN; LOSARTAN; RAMIPRIL; THIAZIDE DIURETIC AGENT; VALSARTAN;

ADD ON THERAPY; ADULT; ARTICLE; BLOOD PRESSURE REGULATION; COST CONTROL; COST MINIMIZATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DOSE RESPONSE; DRUG COST; DRUG DOSE TITRATION; DRUG POTENCY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; PROBABILITY; RECOMMENDED DRUG DOSE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BENZIMIDAZOLES; BIPHENYL COMPOUNDS; COST-BENEFIT ANALYSIS; DRUG COSTS; HUMANS; HYPERTENSION; LOSARTAN; MARKOV CHAINS; TETRAZOLES; VALINE;

EID: 39749145786     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079908X260880     Document Type: Article

References (25)

1. Prescription cost analysis for England: 1998-2006. Department of Health. Available at: http://www.dh.gov.uk/en/PublicationsAndStatistics/Statistics/ StatisticalWorkAreas/StatisticalHealthCare/DH_4086488
2. Prescription cost analysis for Scotland: 2001-2006. Scottish Health Statistics. Available at: http://www.isdscotland.org/isd/info3.jsp?pContentID= 2241&p_applic=CCC&p_service=Content.show&
3. Prescription cost analysis for Wales: 2001-2006. Health of Wales Information Service (Publicly available - provided on request to the author)
4. Prescription cost analysis for Northern Ireland: 2000-2006. Central Services Agency Available at: http://www.centralservicesagency.com/display/ statistics
5. Usher-Smith JA, Ramsbottom T, Pearmain H, Kirby M. Evaluation of the cost savings and clinical outcomes of switching patients from atorvastatin to simvastatin and losartan to candesartan in a Primary Care setting. Int J Clin Pract 2007;61:15-23
6. Minas R. Statin utilization - recognizing the role of the invisible hand. Int J Clin Pract 2007;61:3-6
7. Moon JC, Bogle RG. How to lose a billion pounds. Int J Clin Pract 2007;61:2-3
8. National Audit Office. Prescribing costs in primary care. London 2007. Available at: http://www.nao.org.uk/publications/nao_reports/06-07/0607454.pdf
9. Department of Health Health Survey for England 2003 London 2004. Available at: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/ PublicationsStatistics/DH_4098712
10. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-26
11. Baguet JP, Robitail S, Boyer L, et al. A meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Am J Cardiovasc Drugs 2005;5:131-40
12. Baguet JP, Legallicier B, Auquier P, Robitail S. Updated meta-analytical approach to the efficacy of antihypertensive drugs in reducing blood pressure. Clin Drug Invest 2007;27:735-53
13. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004;6:569-77
14. MIMS July 2007. Haymarket Medical Publishing
15. Van Wijk BL, Klungel OH, Heerdink ER, de Boer BA. Generic substitution of antihypertensive drugs: does it affect adherence? Ann Pharmacother 2006;40:15-20
16. Van Wijk BL, Klungel OH, Heerdink ER, de Boer BA. The association between compliance with antihypertensive drugs and modification of antihypertensive drug regimen. J Hypertens 2004;22:1831-7
17. Enlund H, Jokisalo E, Wallenius S, Korhonen M. Patient-perceived problems, compliance, and the outcome of hypertension treatment. Pharm World Sci 2001;23:60-4
18. Yiannakopoulou EC, Papadopulos JS, Cokkinos DV, Mountokalakis TD. Adherence to antihypertensive treatment: a critical factor for blood pressure control. Eur J Cardiovasc Prev Rehabil 2005;12:243-9
19. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363:2022-31
20. Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875-86
21. Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995-1003
22. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91, 318
23. Oparil S, Guthrie R, Lewin AJ, et al. An elective-titration study of the comparative effectiveness of two angiotensin II-receptor blockers, irbesartan and losartan [Irbesartan/Losartan Study Investigators]. Clin Ther 1998;20:398-409
24. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-95
25. Manolis AJ, Grossman E, Jelakovic B, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension [Losartan Trial Investigators]. Clin Ther 2000;22:1186-203